The latest in multiple myeloma: a European and US perspective
The latest in multiple myeloma: a European and US perspective
Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia
Transplantation combined with novel agents optimal treatment for multiple myeloma
Monoclonal antibodies and multiple myeloma
Factors influencing response to blinatumomab in relapsed/refractory ALL
DNMT3A R882 mutations promote chemoresistance and residual disease in AML
Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma
Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma
ASCO 2015: Latest developments in multiple myeloma
Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma
Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs
Developments in clinical trials and health information technology that will improve targeted therapies for patients